Clinical Trial

Men's Perceptions, Attitudes, and Knowledge Levels Toward Cancer Screening

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Countries are establishing national and international cancer control programs in response to cancer, which has become a global problem. Therefore, cancer is a disease that can be combated not only through investments in treatment, but also through efforts focused on prevention and early diagnosis. According to GLOBOCAN 2022 data, more than 51% of all cancer cases worldwide occur in men. The three most common types of cancer in men are lung cancer, prostate cancer, and colorectal cancer. Increasing awareness, attitudes, and knowledge levels regarding cancer screenings, especially for preventable diseases, will increase participation in screening programs. Increased knowledge levels will translate into positive health behaviors. This study will be conducted as a randomized controlled trial to determine the effect of the Cancer Screenings Education for Men (CASEM) intervention on men's perceptions, attitudes, and knowledge regarding cancer screening programs. Research data will be collected at a public institution between September 2025 and September 2026. The study sample will consist of a total of 78 male individuals, including 39 experimental and 39 control groups that meet the inclusion criteria. Male individuals will be assigned to the experimental and control groups using stratified randomization. The Individual Identification Form, Cancer Screening Perception Scale, Cancer Screening Attitude Scale, and Cancer Screening Knowledge Scale will be used. IBM SPSS 29.0 software will be used to analyze the data obtained from the study. This study will be an important one that addresses Turkey's future vision within the scope of the Twelfth Development Plans and supports the goals and policy measures of the development plan. In addition, our study serves the Sustainable Development Goals, which are among the most important global goals in the context of sustainability. It is expected to have implications for health practices and planning.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-07-25; most recent amendment 2026-01-18.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-09-15
Trial Details
NCT Number NCT07087834
Lead Sponsor Pamukkale University
Collaborators: The Scientific and Technological Research Council of Turkey
Conditions Men's Health Screening, Cancer Screening
Enrollment 78 participants
Start Date 2025-09-01
Primary Completion 2025-09-30 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-21